Breakdown in peripheral tolerance in type 1 diabetes in mice and humans

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 3, 2012, Pages

  Jeker, Lukas T ^a   Bour Jordan, Hélène ^a   Bluestone, Jeffrey A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; BELATACEPT; CD3 ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EXENDIN 4; FC RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; LYMPHOCYTE ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MICRORNA; PROGRAMMED DEATH 1 RECEPTOR; RAPAMYCIN; TEPLIZUMAB; THYMOCYTE ANTIBODY; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; AUTOANTIGEN;

APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CLINICAL TRIAL (TOPIC); COMMENSAL; ENVIRONMENTAL FACTOR; HUMAN; HYGIENE HYPOTHESIS; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOTHERAPY; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; T CELL DEPLETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; DISEASE COURSE; GENETIC ASSOCIATION; IMMUNOLOGY; NONOBESE DIABETIC MOUSE; PANCREAS ISLET; PHYSIOLOGY; REVIEW;

MUS;

ANIMALS; AUTOANTIGENS; AUTOIMMUNITY; CTLA-4 ANTIGEN; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INTERLEUKIN-2; ISLETS OF LANGERHANS; MICE; MICE, INBRED NOD; PERIPHERAL TOLERANCE; T-LYMPHOCYTES, REGULATORY;

EID: 84885957703     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a007807     Document Type: Article

References (192)

1. Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palmer M, Harris RA, Robertson JA, Lernmark A. 2005. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 19: 238-246.
2. Agardh CD, Lynch KF, Palmer M, Link K, Lernmark A. 2009. GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia 52: 1363-1368.
3. Alejandro R, Barton FB, Hering BJ, Wease S. 2008. 2008 Update from the Collaborative Islet Transplant Registry. Transplantation 86: 1783-1788.
4. Allen HF, Klingensmith GJ, Jensen P, Simoes E, Hayward A, Chase HP. 1999. Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study. Diabetes Care 22: 1703-1707.
5. Alleva DG, Maki RA, Putnam AL, Robinson JM, Kipnes MS, Dandona P, Marks JB, Simmons DL, Greenbaum CJ, Jimenez RG, et al. 2006. Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope. Scand J Immunol 63: 59-69.
6. Amrani A, Verdaguer J, Serra P, Tafuro S, Tan R, Santamaria P. 2000. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature 406: 739-742.
7. Anderson MS, Bluestone JA. 2005. The NOD mouse: A model of immune dysregulation. Annu Rev Immunol 23: 447-485.
8. Araki M, Chung D, Liu S, Rainbow DB, Chamberlain G, Garner V, Hunter KM, Vijayakrishnan L, Peterson LB, Oukka M, et al. 2009. Genetic evidence that the differential expression of the ligand-independent isoform of CTLA-4 is the molecular basis of the Idd5. 1 type 1 diabetes region in nonobese diabetic mice. J Immunol 183: 5146-5157.
9. Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, Roep BO, PeakmanM. 2004. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 113: 451-463.
10. Ausubel LJ, Chodos A, Bekarian N, Abbas AK, Walker LS. 2002. Functional tolerance is maintained despite proliferation of CD4 T cells after encounter with tissue-derived antigen. Dev Immunol 9: 173-176.
11. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. 2008. The impact of microRNAs on protein output. Nature 455: 64-71.
12. Bailey-Bucktrout SL, Bluestone JA. 2011. Regulatory T cells: Stability revisited. Trends Immunol 32: 301-306.
13. Barker JM, McFann KK, Orban T. 2007. Effect of oral insulin on insulin autoantibody levels in the Diabetes Prevention Trial Type 1 oral insulin study. Diabetologia 50: 1603-1606.
14. Barron L, Dooms H, Hoyer KK, Kuswanto W, Hofmann J, O'Gorman WE, AbbasAK. 2010. Cutting edge: Mechanisms of IL-2-dependent maintenance of functional regulatory T cells. J Immunol 185: 6426-6430.
15. Bartel DP. 2009. MicroRNAs: Target recognition and regulatory functions. Cell 136: 215-233.
16. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. 2003. TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9: 1202-1208.
17. Bending D, De La Pena H, Veldhoen M, Phillips JM, Uyttenhove C, Stockinger B, Cooke A. 2009. Highly purified Th17 cells from BDC2. 5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Invest 119: 565-572.
18. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, KellyTE, Saulsbury FT, Chance PF, Ochs HD. 2001. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27: 20-21.
19. Bezman NA, Cedars E, Steiner DF, Blelloch R, Hesslein DG, Lanier LL. 2010. Distinct requirements of microRNAs in NK cell activation, survival, and function. J Immunol 185: 3835-3846.
20. + Tregs. J Clin Invest 115: 2904-2913.
21. Bluestone JA, Liu W, Yabu JM, Laszik ZG, Putnam A, Belingheri M, Gross DM, Townsend RM, Vincenti F. 2008. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 8: 2086-2096.
22. Bluestone JA, Herold K, Eisenbarth G. 2010. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464: 1293-1300.
23. Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, Kalwani M, Garcia-Flores Y, Luong M, Devrekanli A, Xu J, et al. 2011. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 208: 1189-1201.
24. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, MacMurray J, Meloni GF, Lucarelli P, Pellecchia M, et al. 2004. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 36: 337-338.
25. Bottini N, Vang T, Cucca F, Mustelin T. Role of PTPN 22 in type 1 diabetes other autoimmune diseases. 2006. Semin Immunol 18: 207-213.
26. Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Kontgen F, Adams JM, Strasser A. 1999. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286: 1735-1738.
27. Bour-Jordan H, Salomon BL, Thompson HL, Szot GL, Bernhard MR, BluestoneJA. 2004. Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest 114: 979-987.
28. Bour-Jordan H, Salomon BL, Thompson HL, Santos R, Abbas AK, Bluestone JA. 2007. Constitutive expression of B7-1 on B cells uncovers autoimmunity toward the B cell compartment in the nonobese diabetic mouse. J Immunol 179: 1004-1012.
29. Bour-Jordan H, Bluestone JA. 2009. Regulating the regulators: Costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev 229: 41-66.
30. Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. 2011. Intrinsic and extrinsic control of peripheral T cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol Rev 241: 180-205.
31. Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, von HerrathM. 2006. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 116: 1371-1381.
32. Chaillous L, Lefevre H, Thivolet C, Boitard C, Lahlou N, Atlan-Gepner C, Bouhanick B, Mogenet A, Nicolino M, Carel JC, et al. 2000. Oral insulin administration and residual β-cell function in recent-onset type 1 diabetes: A multicentre randomised controlled trial. Diabete Insuline Orale group. Lancet 356: 545-549.
33. Chatenoud L, Thervet E, Primo J, Bach JF. 1994. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci 91: 123-127.
34. Chatenoud L, Primo J, Bach JF. 1997. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 158: 2947-2954.
35. + regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 326: 986-991.
36. Chen Z, Benoist C, Mathis D. 2005. How defects in central tolerance impinge on a deficiency in regulatory T cells. Proc Natl Acad Sci 102: 14735-14740.
37. Chong MM, Rasmussen JP, Rudensky AY, Littman DR. 2008. The RNAseIII enzyme Drosha is critical in T cells for preventing lethal inflammatory disease. J Exp Med 205: 2005-2017.
38. Cobb BS, Nesterova TB, Thompson E, Hertweck A, O'Connor E, Godwin J, Wilson CB, Brockdorff N, Fisher AG, Smale ST, et al. 2005. T cell lineage choice and differentiation in the absence of the RNase III enzyme Dicer. J Exp Med 201: 1367-1373.
39. Cobb BS, Hertweck A, Smith J, O'Connor E, Graf D, Cook T, Smale ST, Sakaguchi S, Livesey FJ, Fisher AG, et al. 2006. A role for Dicer in immune regulation. J Exp Med 203: 2519-2527.
40. + regulatory T cells via a TGF-β and retinoic acid-dependent mechanism. J Exp Med 204: 1757-1764.
41. Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, MadeiraMI, Malmegrim KC, Foss-Freitas MC, Simoes BP, et al. 2009. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA301: 1573-1579.
42. D'Alise AM, Auyeung V, Feuerer M, Nishio J, Fontenot J, Benoist C, Mathis D. 2008. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc Natl Acad Sci 105: 19857-19862.
43. Debray-Sachs M, Carnaud C, Boitard C, Cohen H, Gresser I, Bedossa P, Bach JF. 1991. Prevention of diabetes in NOD mice treated with antibody to murine IFN γ. J Autoimmun 4: 237-248.
44. +/- mice. Science 285: 2122-2125.
45. Dissanayake D, Gronski MA, Lin A, Elford AR, Ohashi PS. 2011. Immunological perspective of self versus tumor antigens: Insights from the RIP-gp model. Immunol Rev 241: 164-179.
46. DPT-Type 1 Diabetes Study Group. 2002. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 346: 1685-1691.
47. Eggena MP, Walker LS, Nagabhushanam V, Barron L, Chodos A, Abbas AK. 2004. Cooperative roles of CTLA-4 and regulatory T cells in tolerance to an islet cell antigen. J Exp Med 199: 1725-1730.
48. Elias D, Meilin A, Ablamunits V, Birk OS, Carmi P, Konen-Waisman S, Cohen IR. 1997. Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various β-cell antigens. Diabetes 46: 758-764.
49. Elliott JF, Marlin KL, Couch RM. 1998. Effect of bacille Calmette-Guerin vaccination on C-peptide secretion in children newly diagnosed with IDDM. Diabetes Care 21: 1691-1693.
50. Ergun-Longmire B, Marker J, Zeidler A, Rapaport R, Raskin P, Bode B, Schatz D, Vargas A, Rogers D, Schwartz S, et al. 2004. Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes. Ann NY Acad Sci 1029: 260-277.
51. Esensten JH, Lee MR, Glimcher LH, Bluestone JA. 2009. T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. J Immunol 183: 75-82.
52. Fabian MR, Sonenberg N, Filipowicz W. 2010. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 79: 351-379.
53. Feuerer M, Shen Y, Littman DR, Benoist C, Mathis D. 2009. How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity 31: 654-664.
54. Fife BT, Bluestone JA. 2008. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 224: 166-182.
55. Fife BT, Griffin MD, Abbas AK, Locksley RM, Bluestone JA. 2006a. Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J Clin Invest 116: 2252-2261.
56. Fife BT, Guleria I, Gubbels Bupp M, Eagar TN, Tang Q, Bour-Jordan H, Yagita H, Azuma M, Sayegh MH, Bluestone JA. 2006b. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med 203: 2737-2747.
57. + regulatory T cells. Nat Immunol 4: 330-336.
58. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. 2005. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6: 1142-1151.
59. Fox CJ, Danska JS. 1997. IL-4 expression at the onset of islet inflammation predicts nondestructive insulitis in nonobese diabetic mice. J Immunol 158: 2414-2424.
60. Gardner JM, Devoss JJ, Friedman RS, Wong DJ, Tan YX, Zhou X, Johannes KP, SuMA, Chang HY, Krummel MF, et al. 2008. Deletional tolerance mediated by extrathymic Aire-expressing cells. Science 321: 843-847.
61. Gardner JM, Fletcher AL, Anderson MS, Turley SJ. 2009. AIRE in the thymus and beyond. Curr Opin Immunol 21: 582-589.
62. Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA, Rudensky AY. 2007. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445: 771-775.
63. + T cells and enables CpG oligodeoxynucleotide-mediated costimulation. Immunity 25: 783-793.
64. Gottlieb P, Colman PG, Solvason N, Otto K, Roep B, Harrison LC, Eisenbarth G, Robinson W, Utz PJ, Steinman L, Garren H, Quan J. 2010. One-year results from a phase 1/2 clinical trial of BHT-3021, a DNA plasmid vaccine for type 1 diabetes (T1D). In ADA 70th Scientific Sessions June 2010.
65. Griffin MD, Hong DK, Holman PO, Lee KM, Whitters MJ, O'Herrin SM, FallarinoF, Collins M, Segal DM, Gajewski TF, et al. 2000. Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). J Immunol 164: 4433-4442.
66. Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, Cagnard N, Carpentier W, Tang Q, Bluestone J, et al. 2010. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 20: 1871.
67. Gronski MA, Boulter JM, Moskophidis D, Nguyen LT, Holmberg K, Elford AR, Deenick EK, Kim HO, Penninger JM, Odermatt B, et al. 2004. TCR affinity and negative regulation limit autoimmunity. Nat Med 10: 1234-1239.
68. Guo H, Ingolia NT, Weissman JS, Bartel DP. 2010. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466: 835-840.
69. Haasch D, Chen YW, Reilly RM, Chiou XG, Koterski S, Smith ML, Kroeger P, McWeeny K, Halbert DN, Mollison KW, et al. 2002. T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC. Cell Immunol 217: 78-86.
70. Haller MJ, Atkinson MA, Schatz DA. 2010. Efforts to prevent and halt autoimmune β cell destruction. Endocrinol Metab Clin North Am 39: 527-539.
71. - (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med 187: 1047-1056.
72. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, et al. 2002. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346: 1692-1698.
73. Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA. 2003. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala). J Clin Invest 111: 409-418.
74. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA. 2005. A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54: 1763-1769.
75. Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, et al. 2009. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol 132: 166-173.
76. Hezova R, Slaby O, Faltejskova P, Mikulkova Z, Buresova I, Raja KR, Hodek J, Ovesna J, Michalek J. 2010. microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell Immunol 260: 70-74.
77. Hori S, Nomura T, Sakaguchi S. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061.
78. Hou B, Reizis B, DeFranco AL. 2008. Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and-extrinsic mechanisms. Immunity 29: 272-282.
79. Hou B, Saudan P, Ott G, Wheeler ML, Ji M, Kuzmich L, Lee LM, Coffman RL, Bachmann MF, Defranco AL. 2011. Selective utilization of toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity 34: 375-384.
80. Hoyne GF, Flening E, Yabas M, Teh C, Altin JA, Randall K, Thien CB, LangdonWY, Goodnow CC. 2011. Visualizing the role of Cbl-b in control of islet-reactive CD4 T cells and susceptibility to type 1 diabetes. J Immunol 186: 2024-2032.
81. Hultgren B, Huang X, Dybdal N, Stewart TA. 1996. Genetic absence of γ-interferon delays but does not prevent diabetes in NOD mice. Diabetes 45: 812-817.
82. Jeker LT, Bluestone JA. 2010. Small RNA regulators of T cell-mediated autoimmunity. J Clin Immunol 30: 347-357.
83. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH, Sharpe AH. 2006. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203: 883-895.
84. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, HaleG, Gorus F, Goldman M, Walter M, Candon S, et al. 2005. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352: 2598-2608.
85. + T regulatory cells. Nat Immunol 4: 337-342.
86. Kim JM, Rasmussen JP, Rudensky AY. 2007. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 8: 191-197.
87. Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Campbell DJ. 2009. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol 10: 595.
88. Kohlhaas S, Garden OA, Scudamore C, Turner M, Okkenhaug K, Vigorito E. 2009. Cutting edge: The Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol 182: 2578-2582.
89. Koralov SB, Muljo SA, Galler GR, Krek A, Chakraborty T, Kanellopoulou C, Jensen K, Cobb BS, Merkenschlager M, Rajewsky N, et al. 2008. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell 132: 860-874.
90. Korn T, Bettelli E, Oukka M, Kuchroo VK. 2009. IL-17 and Th17 Cells. Annu Rev Immunol 27: 485-517.
91. Lee JW, Epardaud M, Sun J, Becker JE, Cheng AC, Yonekura AR, Heath JK, TurleySJ. 2007. Peripheral antigen display by lymph node stroma promotes T cell tolerance to intestinal self. Nat Immunol 8: 181-190.
92. Lennon GP, Bettini M, Burton AR, Vincent E, Arnold PY, Santamaria P, VignaliDA. 2009. T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event. Immunity 31: 643-653.
93. Lenschow DJ, Herold KC, Rhee L, Patel B, Koons A, Qin HY, Fuchs E, Singh B, Thompson CB, Bluestone JA. 1996. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 5: 285-293.
94. Lieberman SM, DiLorenzo TP. 2003. A comprehensive guide to antibody and T-cell responses in type 1 diabetes. Tissue Antigens 62: 359-377.
95. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM. 2005. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433: 769-773.
96. Liston A, Lu LF, O'Carroll D, Tarakhovsky A, Rudensky AY. 2008. Dicer-dependent microRNA pathway safeguards regulatory T cell function. J Exp Med 205: 1993-2004.
97. + T reg cells. J Exp Med 203: 1701-1711.
98. Liu X, Alexiou M, Martin-Orozco N, Chung Y, Nurieva RI, Ma L, Tian Q, KolliasG, Lu S, Graf D, et al. 2009. Cutting edge: A critical role of B and T lymphocyte attenuator in peripheral T cell tolerance induction. J Immunol 182: 4516-4520.
99. +regulatory T-cells of type 1 diabetic subjects. Diabetes 59: 407-415.
100. Lu LF, Thai TH, Calado DP, Chaudhry A, Kubo M, Tanaka K, Loeb GB, Lee H, Yoshimura A, Rajewsky K, et al. 2009. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 30: 80-91.
101. Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, Yoshimura A, Baltimore D, Rudensky AY. 2010. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 142: 914-929.
102. Ludvigsson J. 2009. Therapy with GAD in diabetes. Diabetes Metab Res Rev 25: 307-315.
103. Ludvigsson J, Faresjo M, Hjorth M, Axelsson S, Cheramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, et al. 2008. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 359: 1909-1920.
104. Ludvigsson J, Hjorth M, Cheramy M, Axelsson S, Pihl M, Forsander G, NilssonNO, Samuelsson BO, Wood T, Aman J, et al. 2011. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: A randomised controlled trial. Diabetologia 54: 634-640.
105. Luhder F, Hoglund P, Allison JP, Benoist C, Mathis D. 1998. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med 187: 427-432.
106. Luhder F, Chambers C, Allison JP, Benoist C, Mathis D. 2000. Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. Proc Natl Acad Sci 97: 12204-12209.
107. Luo X, Pothoven KL, McCarthy D, DeGutes M, Martin A, Getts DR, Xia G, He J, Zhang X, Kaufman DB, et al. 2008. ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms. Proc Natl Acad Sci 105: 14527-14532.
108. Lyons PA, Armitage N, Argentina F, Denny P, Hill NJ, Lord CJ, Wilusz MB, Peterson LB, Wicker LS, Todd JA. 2000. Congenic mapping of the type 1 diabetes locus, Idd3, to a 780-kb region of mouse chromosome 3: Identification of a candidate segment of ancestral DNA by haplotype mapping. Genome Res 10: 446-453.
109. Malek TR, Yu A, Vincek V, Scibelli P, Kong L. 2002. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rβ-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17: 167-178.
110. Marson A, Kretschmer K, Frampton GM, Jacobsen ES, Polansky JK, MacIsaacKD, Levine SS, Fraenkel E, von Boehmer H, Young RA. 2007. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 445: 931-935.
111. Martin-Orozco N, Chung Y, Chang SH, Wang YH, Dong C. 2009. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol 39: 216-224.
112. Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M, ITN-JDRF Type, 1 Diabetes Combination Therapy Assessment Group. 2010. Developing combination immunotherapies for type 1 diabetes: Recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol 160: 176-184.
113. McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, Hulme MA, HoffmullerU, Baron U, Olek S, Bluestone JA, et al. 2011. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol 186: 3918-3926.
114. McInerney MF, Pek SB, Thomas DW. 1991. Prevention of insulitis and diabetes onset by treatment with complete Freund's adjuvant in NOD mice. Diabetes 40: 715-725.
115. Meagher C, Tang Q, Fife BT, Bour-Jordan H, Wu J, Pardoux C, Bi M, Melli K, Bluestone JA. 2008. Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice. J Immunol 180: 7793-7803.
116. Miller SD, Turley DM, Podojil JR. 2007. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat Rev Immunol 7: 665-677.
117. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel RA, et al. 2002. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415: 536-541.
118. Mueller R, Krahl T, Sarvetnick N. 1996. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 184: 1093-1099.
119. Nanto-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, Korhonen S, Erkkola R, Sipila JI, Haavisto L, et al. 2008. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: A double-blind, randomised controlled trial. Lancet 372: 1746-1755.
120. Nielsen C, Hansen D, Husby S, Jacobsen BB, Lillevang ST. 2003. Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens 62: 492-497.
121. O'Connell RM, Kahn D, Gibson WS, Round JL, Scholz RL, Chaudhuri AA, KahnME, Rao DS, Baltimore D. 2010. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 33: 607-619.
122. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, et al. 2011. Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled trial. Lancet 378: 412-419.
123. + T cells. Science 327: 1098-1102.
124. Ogawa N, List JF, Habener JF, Maki T. 2004. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 53: 1700-1705.
125. Ogawa N, Minamimura K, Kodaka T, Maki T. 2006. Short administration of polyclonal anti-T cell antibody (ALS) in NOD mice with extensive insulitis prevents subsequent development of autoimmune diabetes. J Autoimmun 26: 225-231.
126. Okada H, Kuhn C, Feillet H, Bach JF. 2010. The "hygiene hypothesis" for autoimmune and allergic diseases: An update. Clin Exp Immunol 160: 1-9.
127. Orban T, Farkas K, Jalahej H, Kis J, Treszl A, Falk B, Reijonen H, Wolfsdorf J, Ricker A, Matthews JB, et al. 2010. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 34: 408-415.
128. Penaranda C, Tang Q, Bluestone JA. 2011. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol 187: 2015-2022.
129. Ploix C, Bergerot I, Fabien N, Perche S, Moulin V, Thivolet C. 1998. Protection against autoimmune diabetes with oral insulin is associated with the presence of IL-4 type 2 T-cells in the pancreas and pancreatic lymph nodes. Diabetes 47: 39-44.
130. Posselt AM, Szot GL, Frassetto LA, Masharani U, Tavakol M, Amin R, McElroy J, Ramos MD, Kerlan RK, Fong L, et al. 2010. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation 90: 1595-1601.
131. Pozzilli P, Signore A, Williams AJ, Beales PE. 1993. NOD mouse colonies around the world-recent facts and figures. Immunol Today 14: 193-196.
132. Pugliese A, Zeller M, Fernandez A Jr., Zalcberg LJ, Bartlett RJ, Ricordi C, Pietropaolo M, Eisenbarth GS, Bennett ST, Patel DD. 1997. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 15: 293-297.
133. Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, Ghosh T, Atkinson MA, Bluestone JA. 2009. Expansion of human regulatory T cells from patients with type 1 diabetes. Diabetes 58: 652-662.
134. Rahman AH, Cui W, Larosa DF, Taylor DK, Zhang J, Goldstein DR, Wherry EJ, Kaech SM, Turka LA. 2008. MyD88 plays a critical T cell-intrinsic role in supporting CD8 T cell expansion during acute lymphocytic choriomeningitis virus infection. J Immunol 181: 3804-3810.
135. Rapoport MJ, Jaramillo A, Zipris D, Lazarus AH, Serreze DV, Leiter EH, CyopickP, Danska JS, Delovitch TL. 1993. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 178: 87-99.
136. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, van DongenS, Grocock RJ, Das PP, Miska EA, et al. 2007. Requirement of bic/microRNA-155 for normal immune function. Science 316: 608-611.
137. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. 2006. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212: 28-50.
138. Rubtsov YP, Niec RE, Josefowicz S, Li L, Darce J, Mathis D, Benoist C, RudenskyAY. 2010. Stability of the regulatory T cell lineage in vivo. Science 329: 1667-1671.
139. Sadelain MW, Qin HY, Lauzon J, Singh B. 1990. Prevention of type I diabetes in NOD mice by adjuvant immunotherapy. Diabetes 39: 583-589.
140. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12: 431-440.
141. Sanchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, Sabatos CA, Manlongat N, Bender O, Kamradt T, Kuchroo VK, et al. 2003. Tim-3 inhibits T helper type 1-mediated auto-and alloimmune responses and promotes immunological tolerance. Nat Immunol 4: 1093-1101.
142. Saudek F, Havrdova T, Boucek P, Karasova L, Novota P, Skibova J. 2004. Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset. Rev Diabet Stud 1: 80-88.
143. +regulatory T cells. J Immunol 181: 7350-7355.
144. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. 2008. Widespread changes in protein synthesis induced by microRNAs. Nature 455: 58-63.
145. Serreze DV, Chapman HD, Post CM, Johnson EA, Suarez-Pinzon WL, Rabinovitch A. 2001. Th1 to Th2 cytokine shifts in nonobese diabetic mice: Sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation. J Immunol 166: 1352-1359.
146. + regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201: 723-735.
147. Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, Santamaria P, Bluestone JA, Brillantes AM, Herold KC. 2007. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of β-cells. Endocrinology 148: 5136-5144.
148. Simon G, Parker M, Ramiya V, Wasserfall C, Huang Y, Bresson D, Schwartz RF, Campbell-Thompson M, Tenace L, Brusko T, et al. 2008. Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation. Diabetes 57: 405-414.
149. Smith JA, Tso JY, Clark MR, Cole MS, Bluestone JA. 1997. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J Exp Med 185: 1413-1422.
150. Smith JA, Tang Q, Bluestone JA. 1998. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J Immunol 160: 4841-4849.
151. Taganov KD, Boldin MP, Chang KJ, Baltimore D. 2006. NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci 103: 12481-12486.
152. + regulatory T cell: A jack of all trades, master of regulation. Nat Immunol 9: 239-244.
153. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, Masteller EL, McDevitt H, Bonyhadi M, Bluestone JA. 2004. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 199: 1455-1465.
154. Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P, Santamaria P, Locksley RM, Krummel MF, Bluestone JA. 2006. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 7: 83-92.
155. Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, Piccirillo CA, Salomon BL, Bluestone JA. 2008. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28: 687-697.
156. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, Murphy A, FrendeweyD, Valenzuela D, Kutok JL, et al. 2007. Regulation of the germinal center response by microRNA-155. Science 316: 604-608.
157. Thrower SL, James L, Hall W, Green KM, Arif S, Allen JS, Van-Krinks C, Lozanoska-Ochser B, Marquesini L, Brown S, et al. 2009. Proinsulin peptide immunotherapy in type 1 diabetes: Report of a first-in-man Phase I safety study. Clin Exp Immunol 155: 156-165.
158. Tian J, Atkinson MA, Clare-Salzler M, Herschenfeld A, Forsthuber T, LehmannPV, Kaufman DL. 1996. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 183: 1561-1567.
159. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, Bailey R, Nejentsev S, Field SF, Payne F, et al. 2007. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 39: 857-864.
160. Truong W, Hancock WW, Plester JC, Merani S, Rayner DC, Thangavelu G, Murphy KM, Anderson CC, Shapiro AM. 2009. BTLA targeting modulates lymphocyte phenotype, function, and numbers and attenuates disease in nonobese diabetic mice. J Leukoc Biol 86: 41-51.
161. Tsutsumi Y, Jie X, Ihara K, Nomura A, Kanemitsu S, Takada H, Hara T. 2006. Phenotypic and genetic analyses of T-cell-mediated immunoregulation in patients with Type 1 diabetes. Diabet Med 23: 1145-1150.
162. Turley S, Poirot L, Hattori M, Benoist C, Mathis D. 2003. Physiological β cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J Exp Med 198: 1527-1537.
163. Turley SJ, Lee JW, Dutton-Swain N, Mathis D, Benoist C. 2005. Endocrine self and gut non-self intersect in the pancreatic lymph nodes. Proc Natl Acad Sci 102: 17729-17733.
164. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, RainbowDB, Hunter KM, Smith AN, Di Genova G, et al. 2003. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423: 506-511.
165. Vaarala O, Atkinson MA, Neu J. 2008. The "perfect storm" for type 1 diabetes: The complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 57: 2555-2562.
166. van Belle TL, Coppieters KT, von Herrath MG. 2011. Type 1 diabetes: Etiology, immunology, and therapeutic strategies. Physiol Rev 91: 79-118.
167. Vang T, Congia M, Macis MD, Musumeci L, Orru V, Zavattari P, Nika K, Tautz L, Tasken K, Cucca F, et al. 2005. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 37: 1317-1319.
168. Vella A, Cooper JD, Lowe CE, Walker N, Nutland S, Widmer B, Jones R, Ring SM, McArdle W, Pembrey ME, et al. 2005. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am J Hum Genet 76: 773-779.
169. Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, Coutinho M, Malmegrim KC, Foss-Freitas MC, Simoes BP, et al. 2007. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 297: 1568-1576.
170. von Herrath MG, Oldstone MB. 1997. Interferon-γ is essential for destruction of β cells and development of insulin-dependent diabetes mellitus. J Exp Med 185: 531-539.
171. Walker LS, Ausubel LJ, Chodos A, Bekarian N, Abbas AK. 2002. CTLA-4 differentially regulates T cell responses to endogenous tissue protein versus exogenous immunogen. J Immunol 169: 6202-6209.
172. Walter M, Philotheou A, Bonnici F, Ziegler AG, Jimenez R. 2009. No effect of the altered peptide ligand NBI-6024 on β-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care 32: 2036-2040.
173. Wang B, Gonzalez A, Hoglund P, Katz JD, Benoist C, Mathis D. 1998. Interleukin-4 deficiency does not exacerbate disease in NOD mice. Diabetes 47: 1207-1211.
174. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, et al. 2003. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 4: 670-679.
175. Weiner HL. 2001. The mucosal milieu creates tolerogenic dendritic cells and T(R)1 and T(H)3 regulatory cells. Nat Immunol 2: 671-672.
176. Weiner HL, da Cunha AP, Quintana F, Wu H. 2011. Oral tolerance. Immunol Rev 241: 241-259.
177. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, Hu C, Wong FS, Szot GL, Bluestone JA, et al. 2008. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 455: 1109-1113.
178. Wicker LS, Todd JA, Prins JB, Podolin PL, Renjilian RJ, Peterson LB. 1994. Resistance alleles at two non-major histocompatibility complex-linked insulin-dependent diabetes loci on chromosome 3, Idd3 and Idd10, protect nonobese diabetic mice from diabetes. J Exp Med 180: 1705-1713.
179. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S. 2008. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322: 271-275.
180. Wong FS, Wen L, Tang M, Ramanathan M, Visintin I, Daugherty J, Hannum LG, Janeway CA Jr., Shlomchik MJ. 2004. Investigation of the role of B-cells in type 1 diabetes in the NOD mouse. Diabetes 53: 2581-2587.
181. Xiao C, Rajewsky K. 2009. MicroRNA control in the immune system: Basic principles. Cell 136: 26-36.
182. Yamanouchi J, Rainbow D, Serra P, Howlett S, Hunter K, Garner VES., Gonzalez-Munoz A, Clark J, Veijola R, Cubbon R, et al. 2007. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet 39: 329-337.
183. Yip L, Su L, Sheng D, Chang P, Atkinson M, Czesak M, Albert PR, Collier AR, Turley SJ, Fathman CG, et al. 2009. Deaf1 isoforms control the expression of genes encoding peripheral tissue antigens in the pancreatic lymph nodes during type 1 diabetes. Nat Immunol 10: 1026-1033.
184. You S, Chen C, Lee WH, Brusko T, Atkinson M, Liu CP. 2004. Presence of diabetes-inhibiting, glutamic acid decarboxylase-specific, IL-10-dependent, regulatory T cells in naive nonobese diabetic mice. J Immunol 173: 6777-6785.
185. You S, Belghith M, Cobbold S, Alyanakian MA, Gouarin C, Barriot S, Garcia C, Waldmann H, Bach JF, Chatenoud L. 2005. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes 54: 1415-1422.
186. You S, Leforban B, Garcia C, Bach JF, Bluestone JA, Chatenoud L. 2007. Adaptive TGF-β-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci 104: 6335-6340.
187. Zhang L, Nakayama M, Eisenbarth GS. 2008. Insulin as an autoantigen in NOD/human diabetes. Curr Opin Immunol 20: 111-118.
188. Zheng Y, Josefowicz SZ, Kas A, Chu TT, Gavin MA, Rudensky AY. 2007. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 445: 936-940.
189. Zheng Y, Chaudhry A, Kas A, deRoos P, Kim JM, Chu TT, Corcoran L, TreutingP, Klein U, Rudensky AY. 2009. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature 458: 351-356.
190. Zhou X, Jeker LT, Fife BT, Zhu S, Anderson MS, McManus MT, Bluestone JA. 2008. Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med 205: 1983-1991.
191. + T cell lineage differentiation. Immunity 30: 646-655.
192. Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martinez-Llordella M, Ashby M, Nakayama M, Rosenthal W, Bluestone JA. 2009b. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 10: 1000-1007.